This invention concerns the use of a compound of formula (I'), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C.sub.1-6alkyl; C.sub.1-6alkylcarbonyl; C.sub.1-6alkyloxy -carbonyl; aminocarbonyl; C.sub.1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C.sub.1-4alkyl substituted piperidinyl, mono- or di(C.sub.1-6alkyl)amino, aminocarbonyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC.sub.1-4alkyl; cyano; amino; mono- or di(C.sub.1-6alkyl)aminocarbonyl; C.sub.1-6alkyloxycarbonyl; C.sub.1-6alkylcarbonyloxy; aminoS(.dbd.O).sub.2--; mono- or di(C.sub.1-6alkyl)aminoS(.dbd.O).sub.2; --C(.dbd.N--R.sup.x)NR.sup.yR.sup.z; Q is optionally substituted C.sub.3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula (b-1), (b-2), or (b-3), L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-.alpha. and/or IL-12 ##STR00001##